Nasonex (Mometasone Furoate)

Mometasone furoate is a synthetic glucocorticoid that binds to glucocorticoid receptors in nasal mucosal cells. This binding modifies gene expression, leading to decreased production of inflammatory mediators such as cytokines, prostaglandins, and leukotrienes, which in turn reduces swelling, mucus production, and cellular infiltration.

The dose of Nasonex is individualized by the prescribing healthcare professional based on the patient’s age, severity of symptoms, and clinical response. The prescriber determines the number of sprays per nostril and the frequency of administration, typically ranging from once to twice daily.

Safety data for Nasonex in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks and alternatives with their healthcare provider.

To request Nasonex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and assistance with import documentation.

Nasonex (mometasone furoate) is a high‑potency intranasal glucocorticoid with a favorable safety profile when used at recommended doses. Compared with lower‑potency agents such as fluticasone propionate, mometasone often achieves similar symptom control with fewer daily sprays, but individual response and tolerability can vary.

Nasonex should be stored at room temperature, below 25 °C (77 °F). Keep the spray bottle in its original packaging, protect it from moisture, direct sunlight and excessive heat. Do not freeze the product, and discard any remaining spray after the indicated expiration date.

Nasonex is delivered as a metered‑dose nasal spray. The patient gently shakes the bottle, primes it if it is the first use, tilts the head slightly forward, inserts the tip into one nostril, and sprays the prescribed number of actuations while breathing in gently. The process is then repeated in the other nostril if directed.

Serious risks, although rare, include fungal infection of the nasal mucosa, severe or persistent nosebleeds, visual disturbances such as cataracts or glaucoma, systemic adrenal suppression with prolonged high‑dose use, and severe allergic reactions including anaphylaxis. Patients should seek medical attention promptly if any of these occur.

Nasonex should be avoided in individuals with a known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients with active untreated nasal infections until the infection is resolved, and it should be used with caution in children under two years of age.